| Patent application number | Description | Published |
|---|
| 20080242865 | PROCESSES FOR THE PREPARATION OF HYDROXYLAMINES - The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (Ia): | 10-02-2008 |
| 20080248105 | POLYMORPHIC FORMS OF 6-11 BICYCLIC KETOLIDE DERIVATIVES - The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment. | 10-09-2008 |
| 20080262208 | 6-11 Bridged Oxime Erythromycin Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-23-2008 |
| 20080267916 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 10-30-2008 |
| 20080267917 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. | 10-30-2008 |
| 20080267918 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 10-30-2008 |
| 20080269228 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. | 10-30-2008 |
| 20080274080 | AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 11-06-2008 |
| 20080274082 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 11-06-2008 |
| 20080279821 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 11-13-2008 |
| 20080286233 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 11-20-2008 |
| 20080287449 | AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 11-20-2008 |
| 20080292587 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS - The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-27-2008 |
| 20080317712 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 12-25-2008 |
| 20090004140 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES - The present invention discloses compounds of Formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-01-2009 |
| 20090005387 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS - The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 01-01-2009 |
| 20090022689 | C4-SPIRO-PYRROLIDINE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-22-2009 |
| 20090035267 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention. | 02-05-2009 |
| 20090035268 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: | 02-05-2009 |
| 20090035271 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-05-2009 |
| 20090035272 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention. | 02-05-2009 |
| 20090041721 | ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-12-2009 |
| 20090047247 | Pyrrolidine Derivatives - The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-19-2009 |
| 20090047248 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: | 02-19-2009 |
| 20090053175 | SUBSTITUTE PYRROLIDINE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-26-2009 |
| 20090060874 | BICYCLIC PYRROLIDINE DERIVATIVES - The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-05-2009 |
| 20090075915 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-19-2009 |
| 20090098085 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: | 04-16-2009 |
| 20090118506 | 6,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-07-2009 |
| 20090123423 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 05-14-2009 |
| 20090123425 | MACROCYCLIC, PYRIDAZINONE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-14-2009 |
| 20090130059 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-21-2009 |
| 20090131343 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES - The invention provides methods utilizing bridged macrolide or tylosin derivatives for the treatment of patients with inflammatory bowel diseases. The methods of the invention provide for the administration to a patient of a therapeutically effective amount of a bridged macrolide or a tylosin derivative, pharmaceutically acceptable derivatives thereof, and combinations thereof for a period of time sufficient to obtain a desired alleviation of one or more symptoms of the inflammatory bowel disease. | 05-21-2009 |
| 20090142299 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-04-2009 |
| 20090149491 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-11-2009 |
| 20090155210 | OXIMYL HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-18-2009 |
| 20090156800 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS - The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds. | 06-18-2009 |
| 20090175822 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-09-2009 |
| 20090180983 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE - The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-16-2009 |
| 20090180984 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-16-2009 |
| 20090180985 | BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-16-2009 |
| 20090191151 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-30-2009 |
| 20090191153 | OXIMYL MACROCYCLIC DERIVATIVES - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-30-2009 |
| 20090197888 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 08-06-2009 |
| 20090202485 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 08-13-2009 |
| 20090202486 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 08-13-2009 |
| 20090209547 | C-8 HALOGENATED MACROLIDES - The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 08-20-2009 |
| 20090238794 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-24-2009 |
| 20090264380 | 6,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-22-2009 |
| 20090270457 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-29-2009 |
| 20090274657 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-05-2009 |
| 20090274686 | NUCLEOSIDE PHOSPHONATE DERIVATIVES - The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-05-2009 |
| 20090281050 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES - The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-12-2009 |
| 20090281293 | PROCESSES FOR THE PREPARATION OF 2 FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES - The present invention relates to processes and intermediates for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (X-c): | 11-12-2009 |
| 20090281324 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE - The present invention relates generally to novel methods for the synthesis of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (Ia): | 11-12-2009 |
| 20090324544 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-31-2009 |
| 20090324577 | 6-11 Bicyclic Ketolide Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-31-2009 |
| 20090326019 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS - The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-31-2009 |
| 20100003214 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-07-2010 |
| 20100015092 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 01-21-2010 |
| 20100041618 | 6-11 Bridged Oxime Erythromycin Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-18-2010 |
| 20100074863 | ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-25-2010 |
| 20100074889 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES - The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: | 03-25-2010 |
| 20100135960 | ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-03-2010 |
| 20100144608 | Macrocyclic hepatitis C serine protease inhibitors - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 06-10-2010 |
| 20100196316 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 08-05-2010 |
| 20100221214 | LINKED DIBENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-02-2010 |
| 20100221215 | LINKED DIBENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-02-2010 |
| 20100221216 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-02-2010 |
| 20100226882 | LINKED DIIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-09-2010 |
| 20100226883 | LINKED DIIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-09-2010 |
| 20100233122 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-16-2010 |
| 20100260715 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-14-2010 |
| 20100266543 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-21-2010 |
| 20100316607 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-16-2010 |
| 20110008284 | NOVEL CLYCLOSPORIN ANALOGUES - The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections. | 01-13-2011 |
| 20110008285 | NOVEL CYCLOSPORIN ANALOGUES - The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections. | 01-13-2011 |
| 20110008286 | NOVEL PROLINE SUBSTITUTED CYCLOSPORIN ANALOGUES - The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections. | 01-13-2011 |
| 20110008288 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-13-2011 |
| 20110033420 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-10-2011 |
| 20110053856 | METABOLITE DERIVATIVES OF THE HDAC INHIBITOR FK228 - The present invention relates to HDAC inhibitor derivatives, particularly derivatives of the free thiol of metabolites of the HDAC inhibitor FK228, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of diseases associated with HDAC, in particular, tumor or cell proliferation diseases. | 03-03-2011 |
| 20110064695 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
| 20110064696 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
| 20110064697 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
| 20110064698 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
| 20110070196 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-24-2011 |
| 20110070197 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-24-2011 |
| 20110123496 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-26-2011 |
| 20110142798 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-16-2011 |
| 20110189129 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 08-04-2011 |
| 20110206637 | ANTIVIRAL AGENTS - The present invention provides antiviral compounds of formula (I), | 08-25-2011 |
| 20110217261 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION - The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity. | 09-08-2011 |
| 20110218175 | ANTIVIRAL AGENTS - The present invention relates to antiviral compounds of formula (I), | 09-08-2011 |
| 20110250172 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-13-2011 |
| 20110300104 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-08-2011 |
| 20120035352 | 6-11 Bicyclic Ketolide Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-09-2012 |
| 20120039848 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-16-2012 |
| 20120070416 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors - The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-22-2012 |
| 20120076755 | Hepatitis C Virus Inhibitors - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-29-2012 |
| 20120076756 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-29-2012 |
| 20120101031 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 04-26-2012 |
| 20120196792 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 08-02-2012 |
| 20120237480 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES - The present invention relates to 2′-allene-substituted nucleoside derivatives of the general formula (I): | 09-20-2012 |
| 20120295842 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 11-22-2012 |
| 20130078217 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES - The present invention relates to 2′-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): | 03-28-2013 |
| 20130144036 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-06-2013 |
| 20130165641 | 6,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-27-2013 |
| 20130183267 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 07-18-2013 |
| 20130231298 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES - The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-05-2013 |
| 20130295049 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-07-2013 |
| 20130315864 | MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES - The present invention provides nucleoside phosphoramidate compounds of Formula I, | 11-28-2013 |
| 20140073797 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES - The present invention relates to processes and intermediates for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (X-c): | 03-13-2014 |
| 20140135485 | 6-11 BICYCLIC KETOLIDE DERIVATIVES - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-15-2014 |
| 20140148573 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 05-29-2014 |
| 20140154208 | Novel [N-Me-4-hydroxyleucine]-9-Cyclosporin Analogues for Treatment and Prevention of Hepatitis C Infection - The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 06-05-2014 |
| 20140187780 | 6,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-03-2014 |
| 20140187793 | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES - The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic): | 07-03-2014 |
| 20140193363 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-10-2014 |
| 20140194350 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-10-2014 |
| 20140219958 | 5, 6-D2 URIDINE NUCLEOSIDE/TIDE DERIVATIVES - In one aspect, the invention provides compounds represented by Formula I, | 08-07-2014 |
| 20140287992 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 09-25-2014 |
| 20140308243 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-16-2014 |
| 20140316143 | PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a): | 10-23-2014 |
| 20140341851 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-20-2014 |
| 20150056165 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 02-26-2015 |
